acivir 400 dt price purinethol 50 singulair de 5mg detrol 2 mg side effects liposafe – pílula para perder peso de forma natural comprar tadapox tamsulosin hcl 04mg capsules generic flomax micardis 40 plm serevent 120 hub how much is a 30 day supply of zetia mac floxin 750 eulexin precio remeron y sus efectos medicamento mobic precio cefixime 300mg para q sirven las pastillas zyrtec se puede comprar aciclovir sin receta medica pastillas seroquel xr quick step calando midnight oak effect natural uses of noroxin 400mg nizoral cream 2 30gm tube (ketoconazole) flovent 220 fruta acai efectos secundarios renagel 800 mg precio en mexico etodolac er 500 micronase efectos secundarios dermgel lamisil generique moduretic fosamax plus 5600 precio en mexico tabletas singulair 5 mg 90 mg cymbalta side effects how much is amoxicillin 500mg isoptin hta 240 mg augmentin 500 mg presentacion cuanto cuesta el ventolin sin receta citalopram 20 mg 56 comprimidos keppra xr 750 mg side effects digoxin 250 mcg oral tab citalopram 60 g promethazine efectos secundarios aspirin 20 mg azatioprina 50 mg imuran orlistat efectos en la menstruacion para que sirven las pastillas metformin onde comprar dover assa mais leve aldactone 50 mg bula pastillas nitrofurantoina meclizine clorhidrato 25 mg tadapox (tadalafildapoxetine) 80mg acivir 200 dt dosage precio corega tabs cozaar plus efectos secundarios 325 mg aspirin side effects 100 pure hoodia fosamax 30 comprar pariet desconto tablets amitriptyline 25mg como comprar pyridium nos eua co diovan efectos secundarios crestor and 81mg aspirin para que sirve benicar 40 mg 60 mg of fluoxetine for ocd precio januvia 25 mg inderal 80 mg capsule que efectos tiene hydrochlorothiazide apa itu urispas 200 plavix precio mexico 100mg clomid chance of twins citalopram 20 mg 56 comprimidos roxithromycin 50mg efectos adversos del keflex teva olanzapine 10mg isoptin hta 240 mg atacand 16 mg comprimidos singulair granulos 4mg aciclovir generique teva-hydrochlorothiazide 25 mg khasiat urispas 200 trileptal 10 mg remeron 30 mg precio donde comprar sinequanone zoloft mg desyrel dividose 150 mg diamox 500 mg price motrin 400 mg para que sirve pastillas provera para que sirven natural alternatives to vioxx celebrex chloroquine 100 mg flomax precio what is robaxin 750 mg used for trental 100 mg 5 ampul use of amoxil 500 mg antivert 25mg tablets side effects 100 hyaluronic acid cream sominex 25 mg ginseng pastillas prograf precio en argentina precio lioresal retin-a in your 20s avapro dosage 300 mg buy antabuse 500mg buy suprax 400 mg online nizoral pastillas para que sirve cleocin 500mg keppra xr 750 mg side effects precio viramune 500 mg propranolol side effects of zyrtec 10 mg noroxin 500 mg flagyl 250 300 mg wellbutrin high flomax 20 mg mobic ampolla 15 mg clomid precio en farmacia chile ciproterona natural 50ah lithium battery adalat efectos secundarios BioLife Solutions Commences Build-Out of Second GMP Production Suite and Corporate Office Expansion

BioLife Solutions Commences Build-Out of Second GMP Production Suite and Corporate Office Expansion

0

 
Demand for HypoThermosol® and CryoStor®, and New Contract Manufacturing Agreement Driving Growth and Creation of New Jobs       03/05 06:00 AM

 

BOTHELL, Wash., March 5, 2012 /PRNewswire/ — BioLife Solutions, Inc. (BLFS:$0.08,00$0.00,000.00%) , a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, today announced that it has executed an amendment to its current commercial lease to double the square footage of its existing facilities.  The additional space will be dedicated to the build-out of an additional GMP manufacturing clean room suite and space for additional team members, whose jobs are being created by increasing demand for the Company’s biopreservation media products and also a high value contract manufacturing agreement that was executed in late 2011.  BioLife’s operations are located in Monte Villa Farms, a Bothell biotech and data center campus.
(Logo:  http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)
Mike Rice, Chief Executive Officer, commented on the outlook for BioLife by stating, “We’re very pleased to see demand for HypoThermosol and CryoStor continuing to increase.  Our best-in-class proprietary products are now recognized by key opinion leaders and a growing customer base in our strategic market segments of regenerative medicine, biobanking, and drug discovery.  This growth, along with a new contract manufacturing customer we acquired late in 2011, will enable BioLife to create up to 10 additional jobs in manufacturing, quality assurance, sales, and marketing. We estimate ending 2012 with 25 team members and having significantly increased revenue over 2011.”
Shipments to BioLife’s new contract manufacturing customer are anticipated to start in the second quarter of 2012.
Daphne Taylor, Chief Financial Officer remarked on the terms of the lease amendment by stating, “In addition to considering an option to expand within our current campus, we evaluated a number of suitable local properties. In the end, we received a very competitive and supportive offer from our landlord and chose to expand our operations in our existing facilities. We look forward to increasing our manufacturing capacity and the size of our team to meet the growing demand for our products and services.”
About BioLife Solutions (BLFS:$0.08,00$0.00,000.00%)
BioLife Solutions (BLFS:$0.08,00$0.00,000.00%) develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.  The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife’s products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death.  BioLife’s enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions (BLFS:$0.08,00$0.00,000.00%) ‘ actual results to differ materially are discussed in the Company’s recent filings with the Securities and Exchange Commission.  BioLife Solutions (BLFS:$0.08,00$0.00,000.00%) disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. 
Media Relations:Investor Relations:
Len HallMatt Clawson
Allen & Caron IncAllen & Caron Inc
(949) 474-4300(949) 474-4300
len@allencaron.com matt@allencaron.com 
  

SOURCE BioLife Solutions, Inc. (BLFS:$0.08,00$0.00,000.00%)

About

Testing

Share.
Welcome to Investor Stemcell! New to the site? Take a minute and Sign Up Today!